Intravenous Infusions Plc reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was GHS 20.39 million compared to GHS 22.66 million a year ago. Net loss was GHS 3.27 million compared to net income of GHS 1.34 million a year ago.

Basic loss per share from continuing operations was GHS 0.012 compared to basic earnings per share from continuing operations of GHS 0.005 a year ago.